Sanofi/Ad Scientiam presented an interim analysis from the ongoing MS-DETECT (NCT05816122) study, showing that Microsoft (MS) ...
PARIS, FRANCE, FRANCE, June 3, 2025 /EINPresswire.com/ -- On the occasion of World Multiple Sclerosis Day, Ad Scientiam announced that MSCopilot ®, its class IIa ...
Ad Scientiam announces the creation of its U.S. subsidiary, Ad Scientiam Inc., to support the deployment of MSCopilot® in the United States. The launch of Ad Scientiam Inc. in the U.S. marks a major ...
PARIS, FRANCE, February 26, 2025 /EINPresswire.com/ -- Ad Scientiam, a pioneering MedTech company specialized in digital biomarkers, announced today the launch of MS ...
Microsoft Copilot is now offered at the "general availability" commercial-release stage, per a Friday Microsoft announcement. "Microsoft Copilot" is the product name that Microsoft uses for its former ...
Multiple Sclerosis (MS) is a chronic immune-mediated disease of the central nervous system that affects 2.8 million people worldwide. The disease is characterized by early inflammatory demyelination ...
After reading the article on the front page of today's ARS I'm still not sure what exactly MS Copilot does for its $30/month. How does the average Office user benefit? I'm guessing it won't work with ...
Microsoft keeps making news with its AI-powered assistant, Microsoft Copilot, which is now getting a new GPT Builder for "Pros" while the supercharged GPT-4 Turbo model is now available to everyone.
(MENAFN- EIN Presswire) EINPresswire/ -- Ad Scientiam, a global leader in digital biomarkers, today announced the creation of its U.S. subsidiary, Ad Scientiam Inc., incorporated in the state of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results